Background
The rationale behind the use of ethambutol in the standard tuberculosis treatment is to prevent the emergence of resistance to rifampicin in case of primary resistance to isoniazid. We evaluated if early detection of isoniazid resistance using molecular testing allows to use an ethambutol-free regimen.
Objective and Methods
FAST-TB, a phase 4 French multicenter, open-label non-inferiority trial, compared two strategies: PCR-based detection of isoniazid and rifampicin resistance at baseline using Genotype® MTBDRplus v2.0® followed by ethambutol discontinuation if no resistance was detected (PCR arm), and a standard four-drug combination, pending phenotypic drug-susceptibility results (C arm). Adult patients with smear positive pulmonary tuberculosis were enrolled. The primary endpoint was the proportion of patients with treatment success defined as bacteriological and clinical cure at the end of treatment. A non-inferiority margin of 10% was used.
Results
203 patients were randomized, 104 in the PCR arm and 99 in the C arm: 26.6% were female, median age was 37 [IQR: 28-51] years, 72.4% were born in Africa, and 5.4% were HIV-infected. Chest X-ray showed cavities in 64.5% of the cases. Overall, 169 patients met criteria of treatment success: 87/104 (83.7%) in the PCR arm and 82/99 (82.8%) in the C arm with a difference of +0.8% (90%IC: -7.9; 9.6), meeting the non-inferiority criteria in the intention-to-treat population (p = 0.02).
Conclusion
In a setting with low prevalence of primary isoniazid resistance, a three-drug combination with isoniazid, rifampicin, pyrazinamide based on rapid detection of isoniazid resistance using molecular testing was non-inferior to starting the recommended four-drug regimen.